Literature DB >> 8619951

Blocking of CD4 cell receptors for the human immunodeficiency virus type 1 (HIV-1) by chemically modified bovine milk proteins: potential for AIDS prophylaxis.

A R Neurath1, A K Debnath, N Strick, Y Y Li, K Lin, S Jiang.   

Abstract

The chemical transformation of synthetic combinatorial libraries to increase the diversity of compounds of medicinal interest was reported recently. Chemical modification of natural products represents a complementary approach to accomplish this aim. Modification of lysines by aromatic acid anhydrides, preferentially by 3-hydroxyphthalic and trimellitic anhydrides and trimellitic anhydride chloride, converted commonly available proteins (human and bovine serum albumin and casein) into potent inhibitors of (i) binding between the HIV-1 gp 120 envelope glycoprotein and the CD4 cell receptor, probably owing to their binding to CD4, and (ii) infection by HIV-1. Modified bovine milk proteins are also potent HIV-1 inhibitors and may have potential for anti-HIV-1 prophylaxis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8619951     DOI: 10.1002/jmr.300080504

Source DB:  PubMed          Journal:  J Mol Recognit        ISSN: 0952-3499            Impact factor:   2.137


  13 in total

1.  Combinations of 3-hydroxyphthalic anhydride-modified ovalbumin with antiretroviral drug-based microbicide candidates display synergistic and complementary effects against HIV-1 infection.

Authors:  Lin Li; Suiyi Tan; Hong Lu; Lu Lu; Jie Yang; Hong Jin; Shuwen Liu; Shibo Jiang
Journal:  J Acquir Immune Defic Syndr       Date:  2011-04-15       Impact factor: 3.731

Review 2.  Mass Spectrometry-Based Protein Footprinting for Higher-Order Structure Analysis: Fundamentals and Applications.

Authors:  Xiaoran Roger Liu; Mengru Mira Zhang; Michael L Gross
Journal:  Chem Rev       Date:  2020-04-22       Impact factor: 60.622

3.  3-hydroxyphthalic anhydride-modified chicken ovalbumin exhibits potent and broad anti-HIV-1 activity: a potential microbicide for preventing sexual transmission of HIV-1.

Authors:  Lin Li; Lili He; Suiyi Tan; Xinhua Guo; Hong Lu; Zhi Qi; Chungen Pan; Xiuli An; Shibo Jiang; Shuwen Liu
Journal:  Antimicrob Agents Chemother       Date:  2010-03-01       Impact factor: 5.191

4.  Human Papillomavirus (HPV) Entry Inhibitors.

Authors:  Yun Zhu
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

Review 5.  Virus Entry Inhibitors: Past, Present, and Future.

Authors:  Shan Su; Wei Xu; Shibo Jiang
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

6.  Maleic anhydride-modified chicken ovalbumin as an effective and inexpensive anti-HIV microbicide candidate for prevention of HIV sexual transmission.

Authors:  Lin Li; Pengyuan Qiao; Jie Yang; Lu Lu; Suiyi Tan; Hong Lu; Xiujuan Zhang; Xi Chen; Shuguang Wu; Shibo Jiang; Shuwen Liu
Journal:  Retrovirology       Date:  2010-04-26       Impact factor: 4.602

7.  Anti-HIV-1 activity of cellulose acetate phthalate: synergy with soluble CD4 and induction of "dead-end" gp41 six-helix bundles.

Authors:  A Robert Neurath; Nathan Strick; Shibo Jiang; Yun-Yao Li; Asim K Debnath
Journal:  BMC Infect Dis       Date:  2002-04-30       Impact factor: 3.090

8.  Intranasal administration of maleic anhydride-modified human serum albumin for pre-exposure prophylaxis of respiratory syncytial virus infection.

Authors:  Zhiwu Sun; Qian Wang; Ran Jia; Shuai Xia; Yuan Li; Qi Liu; Wei Xu; Jin Xu; Lanying Du; Lu Lu; Shibo Jiang
Journal:  Viruses       Date:  2015-02-16       Impact factor: 5.048

9.  Cellulose acetate phthalate, a common pharmaceutical excipient, inactivates HIV-1 and blocks the coreceptor binding site on the virus envelope glycoprotein gp120.

Authors:  A R Neurath; N Strick; Y Y Li; A K Debnath
Journal:  BMC Infect Dis       Date:  2001-09-25       Impact factor: 3.090

10.  The antiviral activity of naturally occurring proteins and their peptide fragments after chemical modification.

Authors:  Anna Oevermann; Monika Engels; Ursula Thomas; Antonio Pellegrini
Journal:  Antiviral Res       Date:  2003-06       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.